Docquity and Novartis Collaborate to Address Retinal Health in Malaysia

Novartis, a global healthcare company, and Docquity, Southeast Asia's largest network of healthcare professionals (HCPs), have revealed a multi-year collaboration in Malaysia to tackle the increase in retinal health challenges such as age-related macular degeneration (AMD) and diabetic macular edema (DME). The increasing trend of DME is attributed to the country's increasing prevalence of diabetes, now estimated at 20%, or one in every five adults.

With its Awareness to Advocacy (A2A) Program, Novartis uses Docquity's insights-based, omnichannel commercial solutions to increase access to two of its retinal treatments and enhance retinal health education for thousands of ophthalmologists and medical retina specialists across the country.

Novartis interacts with a wide array of its target HCPs through a range of relevant learning channels as part of the A2A Program on Docquity. Aside from live news on medical advancements through social media and chat forums, this also consists of the latest clinical publications, infographics, and live interactive webinars on the Docquity platform.

Docquity's assigned medical representatives deliver tailored online and offline support driven by HCP insights. Moreover, Docquity will facilitate easier participation of HCPs in key industry events, such as those organized by the Malaysian Ophthalmology Society Congress (MOSC).

Docquity will help Novartis increase the reach of its retinal health products across Malaysia through partnerships with a broad variety of regional distributor partners.